ExploreWatchlistsPricing
  1. JP-listed companies
  2. HEALIOS K.K.
  3. Financials
  4. Provision for income taxes

HEALIOS K.K. (4593)

Market cap
¥49.5B
P/E ratio
Helios develops stem cell treatments for hard-to-treat diseases using both somatic stem cells and iPS cells to create regenerative medicines.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndProvision for income taxes (Million JPY)YoY (%)
Dec 31, 2025103-37.95%
Dec 31, 2024166-11.23%
Dec 31, 2023187-216.88%
Dec 31, 2022-160-135.56%
Dec 31, 2021450+233.33%
Dec 31, 2020135+2150.00%
Dec 31, 20196+20.00%
Dec 31, 20185-2.00%
Dec 31, 20175-25.11%
Dec 31, 20167-27352.00%
Dec 31, 2015-0-100.37%
Dec 31, 20147

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat